Trust Company of the South’s TG Therapeutics TGTX Stock Holding History

Trust Company of the South’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$422K	Buy	7,675 +75	+1%	+$3.07K	0.06%	96
2026 Q1	$252K	Sell	7,600 -3,000	-28%	-$89.4K	0.04%	126
2025 Q4	$316K	Hold	10,600	–	–	0.05%	110
2025 Q3	$383K	Hold	10,600	–	–	0.06%	95
2025 Q2	$381K	Hold	10,600	–	–	0.07%	91
2025 Q1	$418K	Hold	10,600	–	–	0.09%	78
2024 Q4	$319K	Hold	10,600	–	–	0.07%	97
2024 Q3	$248K	Hold	10,600	–	–	0.05%	117
2024 Q2	$189K	Hold	10,600	–	–	0.04%	113
2024 Q1	$161K	Hold	10,600	–	–	0.04%	116
2023 Q4	$181K	Buy	+10,600	New	+$123K	0.05%	115

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

PCM

Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Trust Company of the South's TGTX Position: Q2 2026 in Review

Trust Company of the South increased its TG Therapeutics (TGTX) stake by 0.99% in Q2 2026, buying an estimated $3.07K and bringing the position to 7,675 shares worth $422K. The position accounts for 0.06% of the portfolio, ranked #96.

Trust Company of the South first reported a position in TGTX in Q4 2023 and has held it in 11 quarters since. 195 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Trust Company of the South held 7,675 shares of TG Therapeutics worth $422K as of Q2 2026.
Trust Company of the South bought 75 TG Therapeutics shares in Q2 2026, an estimated $3.07K.
TG Therapeutics made up 0.06% of Trust Company of the South's portfolio in Q2 2026, its #96 holding.
Trust Company of the South first reported a position in TG Therapeutics in Q4 2023 and has held it in 11 quarters since.
195 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Trust Company of the South's 13F filing for Q2 2026, filed 1 Jul 2026.